Skip to main content
. 2022 Jan 28;15(2):165. doi: 10.3390/ph15020165

Figure 2.

Figure 2

(A) Some of the best characterized antagonists of the VEGF-A binding to the NRP1 b1 domain. (B) Small-molecules identified as potential antagonists of the spike induced SARS-CoV-2 entry. 1 Cell-free bt-VEGF-A165 binding assay, measuring inhibition of VEGF binding to the b1 domain on NRP1 [35,38,39]. 2 Cell-free bt-VEGF-A165 binding assay measuring inhibition of VEGF binding to the b1 domain on NRP1 at a compound concentration of 10 μM [41]. 3 Vero-E6-TMPRSS2 cell-based assay measuring inhibition of SARS-CoV-2 spike protein dependent entry using GFP-expressing vesicular stomatitis virus (VSV) recombinant protein, encoding the SARS-CoV-2 spike protein [45].